Search results
Celldex Therapeutics Inc (CLDX) Reports Q4 and Full Year 2023 Financial Results
GuruFocus.com via Yahoo Finance· 3 months agoCash Position: Increased to $423.6 million as of December 31, 2023, from $235.3 million as of...
Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 42%?
Simply Wall St. via Yahoo Finance· 1 year agoKey Insights Celldex Therapeutics' estimated fair value is US$54.52 based on 2 Stage Free Cash Flow...
Celldex Therapeutics Inc (CLDX) Q3 2023 Earnings: R&D Expenses Rise Amid Progress in ...
GuruFocus.com via Yahoo Finance· 7 months agoCelldex Therapeutics Inc (NASDAQ:CLDX) reported a net loss of $38.3 million for Q3 2023, compared to a net loss of $26.8 million for Q3 2022. R&D expenses rose to $34.5 million in Q3 2023, up ...
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 3 months agoCelldex (CLDX) delivered earnings and revenue surprises of 25% and 245.77%, respectively, for the...
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. via Yahoo Finance· 1 year agoThere's no doubt that money can be made by owning shares of unprofitable businesses. For example,...
Why Celldex Therapeutics Shares Are Trading Higher Today
Benzinga via Yahoo Finance· 1 year agoCelldex Therapeutics Inc (NASDAQ: CLDX) announced updated data from its Phase 1b trial of...
Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study
Benzinga via Yahoo Finance· 2 years agoCelldex Therapeutics Inc (NASDAQ: CLDX) announced interim data from Phase 1b trial of barzolvolimab...
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely
Simply Wall St. via Yahoo Finance· 2 years agoEven when a business is losing money, it's possible for shareholders to make money if they buy a...
Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study
Zacks via Yahoo Finance· 2 years agoCelldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate,...
Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug
Investor's Business Daily· 2 years agoCelldex Therapeutics took aim at Roche and Novartis' blockbuster hives treatment on Friday with a...